FMFlavia Marzetta

Flavia Marzetta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Flavia Marzetta has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modelling interpretable patient-level representations from structured and simple multimodal data

    by Kazimierz Oksza-Orzechowski, Małgorzata ŁazęCka, Łukasz Koperski, Damian Wójtowicz, Marcin Możejko, Daniel Schulz, Robin Liechti, Flavia Marzetta, Marie Morfouace, Henoch S. Hong, et al.

    Patient cohort profiling increasingly includes structured views for multiple modalities, such as single-cell RNA sequencing, spatial transcriptomics or proteomics, and histology, each providing multiple subobservations per patient, including single cells, spatial spots or patches. To model such data along with simple patient-level views, current multimodal integration methods typically rely on separately precomputed summaries and fail to fully leverage information in structured views. Here we present FACTMx, a variational framework that jointly models structured and simple views to learn interpretable patient-level representations. FACTMx couples latent patient factors with subobservation clustering and per-patient component proportions, enabling direct interpretation and downstream association analyses. The framework supports different structured-view mixture assumptions, including topic- and Gaussian-structured data, while retaining modular encoder-decoder parameterisations. In simulations spanning sparse and dense dependencies and multiple noise regimes, FACTMx improved reconstruction, integration and recovery of structured components relative to previous methods. Applied to non-small cell lung cancer cohorts, FACTMx captured survival-associated latent signals linked to immune microenvironments, gene expression pathways and spatially coherent histological patterns. In a longitudinal coronary syndrome cohort, FACTMx highlighted an outcome-associated axis connected to ejection-fraction change, immune cell states, soluble mediators and cardiac injury markers. These results support joint structured-simple modelling for interpretable multimodal patient stratification.

  • Open Access

    Correction to: Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia

    by Judit Castillo‑Armengol, Flavia Marzetta, Ana Rodriguez Sanchez-Archidona, Christian Fledelius, Mark Evans, Alison McNeilly, Rory J. McCrimmon, Mark Ibberson, Bernard Thorens

  • Open Access

    Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia

    by Judit Castillo-Armengol, Flavia Marzetta, Ana Rodriguez Sanchez-Archidona, Christian Fledelius, Mark Evans, Alison McNeilly, Rory J. McCrimmon, Mark Ibberson, Bernard Thorens

    Aims/hypothesis: Repeated exposures to insulin-induced hypoglycaemia in people with diabetes progressively impairs the counterregulatory response (CRR) that restores normoglycaemia. This defect is characterised by reduced secretion of glucagon and other counterregulatory hormones. Evidence indicates that glucose-responsive neurons located in the hypothalamus orchestrate the CRR. Here, we aimed to identify the changes in hypothalamic gene and protein expression that underlie impaired CRR in a mouse model of defective CRR. Methods: High-fat-diet fed and low-dose streptozocin-treated C57BL/6N mice were exposed to one (acute hypoglycaemia [AH]) or multiple (recurrent hypoglycaemia [RH]) insulin-induced hypoglycaemic episodes and plasma glucagon levels were measured. Single-nuclei RNA-seq (snRNA-seq) data were obtained from the hypothalamus and cortex of mice exposed to AH and RH. Proteomic data were obtained from hypothalamic synaptosomal fractions. Results: The final insulin injection resulted in similar plasma glucose levels in the RH group and AH groups, but glucagon secretion was significantly lower in the RH group (AH: 94.5±9.2 ng/l [n=33]; RH: 59.0±4.8 ng/l [n=37]; pAvp, Pmch and Pcsk1n, and the most overexpressed gene was Kcnq1ot1, as compared with AH-exposed mice. Gene ontology analysis of differentially expressed genes (DEGs) indicated a coordinated decrease in many oxidative phosphorylation genes and reduced expression of vacuolar H+- and Na+/K+-ATPases; these observations were in large part confirmed in the proteomic analysis of synaptosomal fractions. Compared with AH-exposed mice, oligodendrocytes from RH-exposed mice had major changes in gene expression that suggested reduced myelin formation. In astrocytes from RH-exposed mice, DEGs indicated reduced capacity for neurotransmitters scavenging in tripartite synapses as compared with astrocytes from AH-exposed mice. In addition, in neurons and astrocytes, multiple changes in gene expression suggested increased amyloid beta (Aβ) production and stability. The snRNA-seq analysis of the cortex showed that the adaptation to RH involved different biological processes from those seen in the hypothalamus. Conclusions/interpretation: The present study provides a model of defective counterregulation in a mouse model of type 2 diabetes. It shows that repeated hypoglycaemic episodes induce multiple defects affecting all hypothalamic cell types and their interactions, indicative of impaired neuronal network signalling and dysegulated hypoglycaemia sensing, and displaying features of neurodegenerative diseases. It also shows that repeated hypoglycaemia leads to specific molecular adaptation in the hypothalamus when compared with the cortex. Data availability: The transcriptomic dataset is available via the GEO (http://www.ncbi.nlm.nih.gov/geo/), using the accession no. GSE226277. The proteomic dataset is available via the ProteomeXchange data repository (http://www.proteomexchange.org), using the accession no. PXD040183. Graphical


  • Open Access

    Three-dimensional chromatin interactions remain stable upon CAG/CTG repeat expansion

    by Gustavo A. Ruiz Buendía, Marion Leleu, Flavia Marzetta, Ludovica Vanzan, Jennifer Y. Tan, Victor Ythier, Emma L. Randall, Ana C. Marques, Tuncay Baubec, Rabih Murr, et al.

    Expanded CAG/CTG repeats underlie 13 neurological disorders, including myotonic dystrophy type 1 (DM1) and Huntington’s disease (HD). Upon expansion, disease loci acquire heterochromatic characteristics, which may provoke changes to chromatin conformation and thereby affect both gene expression and repeat instability. Here, we tested this hypothesis by performing 4C sequencing at the DMPK and HTT loci from DM1 and HD–derived cells. We find that allele sizes ranging from 15 to 1700 repeats displayed similar chromatin interaction profiles. This was true for both loci and for alleles with different DNA methylation levels and CTCF binding. Moreover, the ectopic insertion of an expanded CAG repeat tract did not change the conformation of the surrounding chromatin. We conclude that CAG/CTG repeat expansions are not enough to alter chromatin conformation in cis. Therefore, it is unlikely that changes in chromatin interactions drive repeat instability or changes in gene expression in these disorders.